# **Special Issue**

# Drug Targeting for CNS Disease

## Message from the Guest Editors

Current treatment of CNS diseases is largely symptomatic, and it does not bring satisfactory therapeutic effects. Today, there is a crucial need to design strategies for new drug development based on a better understanding of the biochemical mechanisms underlying the pathological conditions and on molecular targeting of therapeutic molecules based thereupon. Experimental and clinical observations reveal that nonselective, multipotent drugs appear to be more effective. According to the most recent trends, we should apply therapeutic tools which will simultaneously affect various systems (dual targeting drugs, multitargeting drugs). In this Special Issue, original papers and reviews on neurodegenerative diseases. mental diseases, addictions or cancer as well as molecular targets involved in these diseases are welcome. Covered topics include (but are not limited to) the search for new active compounds (medicines) along with pharmacological and pharmacokinetic evaluation. All preclinical (in vitro, ex vivo, and in vivo tests) as well as clinical studies for the prevention or treatment of CNS diseases are invited.

## **Guest Editors**

## Dr. Dorota Łażewska

Chair of Technology and Biotechnology of Medical Remedies, Faculty of Pharmacy, Jagiellonian University Medical College in Kraków, Ul. Medyczna 9, 30-688 Kraków, Poland

## Dr. Anna Stasiak

Department of Hormone Biochemistry, Medical University of Lodz, Zeligowskiego 7/9, 90-752 Lodz, Poland

## Deadline for manuscript submissions

closed (30 September 2022)



## **Pharmaceutics**

an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/99716

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

#### **Editor-in-Chief**

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

### **Author Benefits**

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

## **Journal Rank:**

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

## **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

